FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

This study has been withdrawn prior to enrollment.

(Study stopped prior to subject enrollment.)

Sponsor:

Information provided by:

United Therapeutics

ClinicalTrials.gov Identifier:

NCT00760916

First received: September 25, 2008

Last updated: January 29, 2013

Last verified: January 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

Study Status:	This study has been withdrawn prior to enrollment.
Study Completion Date:	January 2009
Primary Completion Date:	January 2009 (Final data collection date for primary outcome measure)